non alcoholic fatty liver disease (NAFLD)
Israeli drug effective in combating fatty liver disease - new research - The Jerusalem Post
Significant insight has been gained into our understanding of the pathogenesis of NALFD; however the key metabolic aberrations underlying lipid accumulation in hepatocytes and the progression of NAFLD remain to be elucidated. Accumulating and emerging evidence indicate that hepatic mitochondria play a critical role in the development and pathogenesis of steatosis and NAFLD. Here, we review studies that document a link between the pathogenesis of NAFLD and hepatic mitochondrial dysfunction with particular focus on new insights into the role of impaired fatty acid oxidation, the transcription factor peroxisome proliferator-activated receptor-y coactivator-1a PGC-1a , and sirtuins in development and progression of NAFLD. Nonalcoholic fatty liver disease NAFLD has evolved as the world's epidemic and is one of the most common chronic diseases in the United States [1,2]. NAFLD involves a spectrum of hepatic steatosis, nonalcoholic steatohepatitis NASH , fibrosis, cirrhosis, and hepatocellular carcinoma HCC that occurs in the absence of significant alcohol intake and absence of other viral, genetic and. In addition to genetic risk factors, NAFLD prevalence is aggravated by changes in life style including physical inactivity as well as consumption of high fat and high fructose corn syrup diet .
Immunotherapy of Liver Diseases
A particular type of dendritic cell is responsible for the tissue damage that occurs in non-alcoholic steatohepatits NASH in mice and humans. The dendritic cells cause aggressive, proinflammatory behavior in T cells, as now discovered by researchers from the German Cancer Research Center DKFZ in collaboration with colleagues from Israeli research institutes. Blocking these dendritic cells alleviates symptoms in mice. This type of approach might also prevent the development of serious liver damage in NASH patients.
The purpose of this study is to compare the incidence and frequency of elevated liver enzymes or parenteral IV nutrition-associated liver disease, in adult patients who are receiving daily versus three time per week soybean based intravenus IV fat emulsions. Nonalcoholic fatty liver disease NAFLD is the most common cause of chronic liver disease in the world and a major public health issue in the US. It is estimated to affect 1 in 4 adults and it is most commonly found in people who are overweight or obese.